An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2020
Price : $35 *
At a glance
- Drugs MTX 110 (Primary) ; Gadoteridol
- Indications Glioma
- Focus Adverse reactions; First in man
- 15 Jan 2020 Phase 1 of this study was stopped because the company has completed sufficient safety assessments at highest dose level.Protocol for phase 2 expansion is ongoing
- 11 Oct 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 11 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.